9,538 Results

CHMP positive for Kalydeco to treat patients With cystic fibrosis aged 12 to less than 24 months With certain mutations in the CFTR gene.- Vertex.

 Added 15 hours ago

Vertex Pharmaceuticals (Europe) Limited announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted...

Phase III VOYAGE 1 trial of Tremfya shows response maintained to 3 years in plaque psoriasis.- Janssen.

 Added 15 hours ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new long-term data from the open-label period of the VOYAGE...

HeartMate 3 Heart Pump is now FDA approved for advanced heart failure patients not eligible for a heart transplant. Abbott

 Added 15 hours ago

Abbott announced that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received FDA approval as a destination therapy for...

NETTER-1 data shows improved PFS with Lutathera in neuroendocrine tumours.- Novartis.

 Added 15 hours ago

Novartis announced presentation of a new analysis of Lutathera (lutetium Lu 177 dotatate) NETTER-1 data examining the impact of Lutathera...

CHMP recommends authorisation of lanadelumab for the Prevention of HAE Attacks.- Shire plc

 Added 15 hours ago

Shire plc announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive...

CHMP recommends approval of Ogivri biosimilar for breast cancer and gastric cancer.- Mylan + Biocon.

 Added 15 hours ago

Mylan and Biocon announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a...

hase III FLAURA trial shows MET-amplification and EGFR C797S mutation among most frequent resistance mechanisms to Tagrissoin NSCLC patients. AstraZeneca

 Added 15 hours ago

AstraZeneca presented new data on the mechanisms of acquired resistance from the Tagrisso (osimertinib) pivotal Phase III FLAURA trial during...

CHMP recommends approval of Dengvaxia in dengue disease.- Sanofi.

 Added 15 hours ago

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing...

CHMP recommends Bevespi Aerosphere to treat COPD.- AstraZeneca

 Added 15 hours ago

AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a...

Phase III KEYNOTE-426 trial of Keytruda + Inlyta meets primary endpoints in renal cell carcinoma.- Merck Inc. + Pfizer.

 Added 1 day ago

Merck Inc announced that the pivotal Phase III KEYNOTE-426 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Inlyta...

Load more